Individualizing Neo/Adjuvant Treatment in Early Breast Cancer Care: Education, Tools, and Resources for Patients and Providers

This slideset offers an overview of current risk assessment and biomarker testing used to inform treatment decisions and predict treatment response and prognosis in patients with HER2-negative early breast cancer.

Yara Abdou, MD Released: April 6, 2022

This slideset accompanies an expert analysis of the role of Ki-67 in risk assessment and discusses recently approved adjuvant abemaciclib for patients with HR-positive, HER2-negative EBC at high risk of recurrence.

Yara Abdou, MD Released: May 12, 2022

Downloadable slideset describing germline BRCA mutations, biomarker testing, and adjuvant olaparib in the management of patients with gBRCA1/2-mutated, HER2-negative, high-risk early breast cancer.

Yara Abdou, MD Released: May 17, 2022

Downloadable slideset describing neoadjuvant and adjuvant immunotherapy in high-risk, early-stage triple-negative breast cancer.

Denise A. Yardley, MD
Program Director Released: September 15, 2022

This slideset accompanies an expert analysis of ongoing clinical trials that are most likely to inform care of patients with HR-positive/HER2-negative early-stage breast cancer.

Denise A. Yardley, MD Released: September 22, 2022